肝硬化反覆性腹水的藥物治療

10.6666/ClinMed.201812_82(6).0138

胡彥佶；李癸汌

肝硬化 ； 腹水 ； 治療

臨床醫學月刊

82卷6期（2018 / 12 / 28）

749 - 756

繁體中文

肝硬化併發腹水是不良預後其中一個指標，在定期腹水抽吸搭配白蛋白之外，仍然可以搭配其他藥物控制腹水，並減少病患死亡風險。由於腹水的產生起源於門脈高壓後造成一系列的生理變化，所以在藥物的使用上主要針對這些發生變化的生理系統。針對造成生理變化核心的交感神經系統與腎素－血管收縮素－醛固酮系統(renin-angiotensin-aldosterone system, RAAS)的活化，包含交感神經阻斷劑和多種抗抗利尿激素的藥物皆被用於腹水的控制。

1. (2016).α1 and α2-adrenergic agonists on cirrhotic patients with refractory ascites.Liver Int,36,177-180.
2. Adrian, G,Richard, M,Fabienne, P(2000).Aquaretic effects of niravoline, a rc-opioid with cirrhosis.J Hepatol,32,38-42.
3. Annamalai, A,Wisdom, L,Herada, M(2016).Management of refractory ascites in cirrhosis: Are we out of data?.World J Hepatol,l8,1182-1193.
4. Bari, K,Miñano, C,Shea, M(2012).The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis.Clin Gastroenterol Hepatol,10,1169-1175.
5. Chishina, H,Hagiwara, S,Nishida, N(2016).Clinical factors predicting the effect of tolvaptan for refractory ascites in patients with decompensated liver cirrhosis.Dig Dis,34,659-664.
6. Dahl, E,Gluud, LL,Kimer, N(2012).Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.Aliment Pharmacol Ther,36,619-626.
7. European Association for the Study of Liver(2010).EASL clinical practice guidelines on the management of as cites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.J Hepatol,53,397-417.
8. Eva, M,Eric, EP,Mary, M(2010).Octreotide.J Pain Symptom Management,40,142-148.
9. Ferrarese, Alberto,Zanetto, Alberto,Germani, Giacomo(2016).Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension.World J Hepatol,8,1012-1018.
10. Fimiani, B,Guardia, DD,Puoti, C(2011).The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: A multicentric study.Eur J Intern Med,22,587-590.
11. Iwamoto, T,Maeda, M,Hisanaga, T(2016).Predictors of the effect of tolvaptan on the prognosis of cirrhosis.Intern Med,55,2911-2916.
12. John, S,Thuluvath, PJ(2015).Hyponatremia in cirrhosis: Pathophysiology and management.World J Gastroenterol,21,3197-3205.
13. Jose S, Keith DL, Kristen MR. Ascites in adults with cirrhosis: Diuretic-resistant ascites. Uptodate 2016.
14. Krag, A,Møller, S,Henriksen, JH(2007).Terlipression improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.Hepatology,46,1863-1871.
15. Krag, A,Wiest, R,Albillos, A(2012).The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease.Gut,61,967-969.
16. Kurosaki, M,Izumi, N(2016).Tolvaptan for the Treatment of Refractory Ascites.Intern Med,55,2909-2910.
17. Lenaerts, A, ,CoddenT,Meunier, JC(2006).Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system.Hepatology,44,844-849.
18. Lenz, Kurt,Buder, Robert,Kapun, Lisbeth(2015).Treatment and management of ascites and hepatorenal syndrome: an Update.Therap Adv Gastroenterol,8,83-100.
19. Miñano, Cecilia(2010).Portal Hypertension.Gastroenterol Clin North Am,39,681-695.
20. Moore, CM,Van Thie, DH(2013).Cirrhotic ascites review: Pathophysiology, diagnosis and management.World J Hepatol,5,251-263.
21. Narayen, G,Mandal, SN(2012).Vasopressin receptor antagonists and their role in clinical medicine.Indian J Endocrinol Metab,16,183-191.
22. Ohki, T,Sato, K,Yamada, T(2015).Efficacy of tolvaptan in patients with refractory ascites in a clinical setting.World J Hepatol,7,1685-1693.
23. Reiberger, T,Mandorfer, M(2017).Beta adrener gic block ade and decompensa ted cir rhosis.J Hepatol,66,849-859.
24. Runyon BA. Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012. The American Association for the Study of Liver Diseases 2012.
25. Sansoè, G,Aragno, M,Mastrocola, R(2016).Alpha-2A Adrenoceptor Agonist Guangacine Restores Diuretic Efficiency in Experimental Cirrhotic Ascites: Comparasion with clonidine.PloS One,11,e0158486.
26. Sersté, Thomas,Melot, Christian,Francoz, Claire(2010).Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites.Hepatology,52,1017-1022.
27. Singh, Virendra,Singh, Ajay,Singh, Baljinder(2013).Midodrine and clonidine in patients with Cirrhosis and Refractory or Recurrent Ascites: A randomized Pilot study.Am J Gastroenterol,108,560-567.
28. Tahara, T,Mori, K,Mochizuki, M(2017).Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis.Biomed Rep,7,558-562.
29. Tandon, P,Tsuyuki, RT,Mitchell, L(2009).The effect of 1month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study.Liver Int,29,169-174.
30. Thorhauge, KH,Lindvig, KP,Laleman, W(2016).Lack of consensus for usage of β-blockers in end-stage liver disease.Gut,65,1058-1060.
31. Zhang, X,Wang, SZ,Zheng, JF(2014).Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.World J Gastroenterol,20,11400-11405.

1. 賴欣筠,鄭玉伶,林淑麗(2021)。協助一位膽管癌末期個案因應否認行為不當之護理經驗。長庚護理，32(2)，91-101。
2. 邱鈺佩,林鳳蓮,王湘芸(2023)。一位獨居肝癌末期病人進行善終準備之護理經驗。彰化護理，30(4)，82-93。